Tolerance of the human kidney to isolated controlled ischemia.

Department of Urology, University of Miami Miller School of Medicine, Dominion Tower, 5th Floor, 1400 NW 10th Avenue, Miami, FL 33136. .
Journal of the American Society of Nephrology (Impact Factor: 9.47). 02/2013; 24(3):506-17. DOI: 10.1681/ASN.2012080786
Source: PubMed

ABSTRACT Tolerance of the human kidney to ischemia is controversial. Here, we prospectively studied the renal response to clamp ischemia and reperfusion in humans, including changes in putative biomarkers of AKI. We performed renal biopsies before, during, and after surgically induced renal clamp ischemia in 40 patients undergoing partial nephrectomy. Ischemia duration was >30 minutes in 82.5% of patients. There was a mild, transient increase in serum creatinine, but serum cystatin C remained stable. Renal functional changes did not correlate with ischemia duration. Renal structural changes were much less severe than observed in animal models that used similar durations of ischemia. Other biomarkers were only mildly elevated and did not correlate with renal function or ischemia duration. In summary, these data suggest that human kidneys can safely tolerate 30-60 minutes of controlled clamp ischemia with only mild structural changes and no acute functional loss.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ischemia time during partial nephrectomy is strongly associated with acute and chronic renal injury. ATP depletion during warm ischemia inhibits ATP-dependent processes, resulting in cell swelling, cytoskeletal breakdown and cell death. The duration of ischemia tolerated by the kidney depends on the amount of ATP that can be produced with residual substrates and oxygen in the tissue to sustain cell function. We previously reported that the rat can tolerate 30 min ischemia quite well but 45 min ischemia results in acute kidney injury and progressive interstitial fibrosis. Here we report that pretreatment with SS-20 thirty min prior to warm ischemia in the rat increased ischemia tolerance from 30 min to 45 min. Histological examination of kidney tissues revealed that SS-20 reduced cytoskeletal breakdown and cell swelling after 45 min ischemia. Electron microscopy showed that SS-20 reduced mitochondrial matrix swelling and preserved cristae membranes, suggesting that SS-20 enhanced mitochondrial ATP synthesis under ischemic conditions. Studies with isolated kidney mitochondria showed dramatic reduction in state 3 respiration and respiratory control ratio after 45 min ischemia, and this was significantly improved by SS-20 treatment. These results suggest that SS-20 increases efficiency of the electron transport chain and improves coupling of oxidative phosphorylation. SS-20 treatment after ischemia also significantly reduced interstitial fibrosis. These new findings reveal that enhancing mitochondrial bioenergetics may be an important target for improving ischemia tolerance, and SS-20 may serve well for minimizing acute kidney injury and chronic kidney disease following surgical procedures such as partial nephrectomy and transplantation.
    American journal of physiology. Renal physiology 10/2014; 308(1):ajprenal.00366.2014. DOI:10.1152/ajprenal.00366.2014 · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial dysfunction within the tubular epithelium has been implicated in the pathogenesis of acute kidney injury. Inflammatory, ischemic, or toxic insults dysregulate mitochondrial dynamics, resulting in mitochondrial swelling, fission, and apoptosis. The coordinated processes of generating healthy mitochondria and clearing damaged organelles may contribute to the preservation and restoration of mitochondrial homeostasis. Emerging literature suggests that a master regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptor-γ-coactivator-1α (PGC-1α), is highly expressed in the tubular epithelium of the healthy kidney, and its induction during the post-injury period may contribute to functional recovery from acute kidney injury. © 2014 S. Karger AG, Basel.
    Nephron Clinical Practice 01/2014; 127(1-4):42-5. DOI:10.1159/000363715 · 1.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of an adverse in-utero environment in the programming of chronic kidney disease in the adult offspring is increasingly recognised. The cellular and molecular mechanisms linking the in-utero environment and future disease susceptibility remain unknown. Maternal smoking is a common modifiable adverse in-utero exposure, potentially associated with both mitochondrial dysfunction and epigenetic modification in the offspring. While studies are emerging that point towards a key role of mitochondrial dysfunction in acute and chronic kidney disease, it may have its origin in early development, becoming clinically apparent when secondary insults occur. Aberrant epigenetic programming may add an additional layer of complexity to orchestrate fibrogenesis in the kidney and susceptibility to chronic kidney disease in later life. In this review we explore the evidence for mitochondrial dysfunction and epigenetic modification through aberrant DNA methylation as key mechanistic aspects of fetal programming of chronic kidney disease and discuss their potential use in diagnostics and targets for therapy. Copyright © 2014, American Journal of Physiology - Renal Physiology.
    American journal of physiology. Renal physiology 02/2015; DOI:10.1152/ajprenal.00638.2014 · 3.30 Impact Factor